Arthroscopy journal authors report lower revision and retear rates in some subgroups taking GLP-1s before surgery, with no rise in short-term complications.
Recap by typeshit. Post by @arthroscopyj_atech_asmar on Instagram.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
The companies shared aging clock data from semaglutide and tirzepatide trials at a conference. Geneticist Steve Horvath called a two year effect strong.
A hype-heavy explainer on retatrutide, the Lilly drug that targets three hormone pathways at once. It doesn't add anything new on trials or approval timing.
Loading…